GSNPX
Price
$25.21
Change
+$0.10 (+0.40%)
Updated
Jun 2 closing price
Net Assets
3.55B
VIHAX
Price
$48.62
Change
+$0.31 (+0.64%)
Updated
Jun 2 closing price
Net Assets
19.99B
Interact to see
Advertisement

GSNPX vs VIHAX

Header iconGSNPX vs VIHAX Comparison
Open Charts GSNPX vs VIHAXBanner chart's image
GSNPX vs VIHAX Comparison Chart in %
View a ticker or compare two or three
VS
GSNPX vs. VIHAX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSNPX is a StrongBuy and VIHAX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VIHAX has more cash in the bank: 20B vs. GSNPX (3.55B). VIHAX pays higher dividends than GSNPX: VIHAX (3.40) vs GSNPX (2.32). GSNPX was incepted earlier than VIHAX: GSNPX (8 years) vs VIHAX (10 years). GSNPX (0.83) is less costly to investors than VIHAX (0.16). GSNPX is a more actively managed with annual turnover of: 49.00 vs. VIHAX (9.00). GSNPX has a lower initial minimum investment than VIHAX: GSNPX (0) vs VIHAX (3000). VIHAX annual gain was more profitable for investors over the last year : 26.29 vs. GSNPX (24.09). GSNPX return over 5 years is better than : 78.17 vs. VIHAX (50.19).
GSNPXVIHAXGSNPX / VIHAX
Total Expense Ratio0.800.16500%
Annual Report Gross Expense Ratio0.830.16519%
Fund Existence8 years10 years-
Gain YTD10.27711.25091%
Front LoadN/AN/A-
Min. Initial Investment03000-
Min. Initial Investment IRAN/AN/A-
Net Assets3.55B20B18%
Annual Yield % from dividends2.323.4068%
Returns for 1 year24.0926.2992%
Returns for 3 years70.3164.48109%
Returns for 5 years78.1750.19156%
Returns for 10 yearsN/A102.41-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
API5.260.51
+10.74%
Agora
ECCC24.52-0.02
-0.06%
Eagle Point Credit Company
AR36.26-0.50
-1.36%
ANTERO RESOURCES Corp
HOUR1.93-0.04
-1.83%
Hour Loop
ELVN35.52-1.99
-5.31%
Enliven Therapeutics